Why the study?
Does long-term verapamil monotherapy cause adverse metabolic or hematologic effects in patients with essential hypertension?
Population
45 patients with essential hypertension, mean age 53 years
Design
Cohort, open
Follow-up
mean 5.3 years (range 4 to 8 years)
Authors
Loading...
Verapamil monotherapy was associated with metabolic safety in hypertension; leaves open confirmation of HDL effects and outcomes in randomized trials.
Does long-term verapamil monotherapy cause adverse metabolic or hematologic effects in patients with essential hypertension?
Long-term verapamil monotherapy is metabolically safe and effectively controls blood pressure in patients with essential hypertension, while potentially increasing HDL-cholesterol.
Midtbø et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: